Compugen Ltd (CGEN.OQ)
25 Sep 2018
BRIEF-Compugen Ltd - Bayer Plans To Advance Cancer Immunotherapy Program Into First-In-Human Trials In 2018
* COMPUGEN LTD - BAYER PLANS TO ADVANCE CANCER IMMUNOTHERAPY PROGRAM INTO FIRST-IN-HUMAN TRIALS IN 2018 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)
April 2 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday: ** General Electric Co's healthcare unit said it would sell its information technology business to private equity firm Veritas Capital for $1.05 billion in cash as it sharpens its focus on smart diagnostics and connected devices. ** ReNew Power, backed by Goldman Sachs and Canada Pension Plan Investment Board (CPPIB), said it has acquired Ostro Energy Private Ltd, backed by London-bas
* CO ALSO ELIGIBLE TO RECEIVE UP TO $200 MILLION IN DEVELOPMENT, REGULATORY, COMMERCIAL MILESTONES ON FUTURE PRODUCT SALES Source text (https://bit.ly/2GsywkV) Further company coverage: (Reuters.Brief@thomsonreuters.com)
JERUSALEM Israeli drugmaker Compugen Ltd said it had agreed an exclusive licensing deal with a unit of AstraZeneca to develop antibody products to treat cancer, which could be worth more than $200 million (142.25 million pounds).
JERUSALEM, April 2 Israeli drugmaker Compugen Ltd said it had agreed an exclusive licensing deal with a unit of AstraZeneca to develop antibody products to treat cancer, which could be worth more than $200 million.
|Pfizer Inc. (PFE.N)||$43.79||-0.14|
|Roche Holding Ltd. (ROG.S)||CHF236.15||--|
|Roche Holding Ltd. (RO.S)||CHF237.00||--|
|Abbott Laboratories (ABT.N)||$72.20||+0.76|
|Bristol-Myers Squibb Co (BMY.N)||$61.82||+0.23|
|Bristol-Myers Squibb Co (BMYMP.PK)||$1,034.45||--|
|Amgen, Inc. (AMGN.OQ)||$206.46||-0.75|
|Quest Diagnostics Inc (DGX.N)||$107.59||0.00|